Загрузка...
Pharmacokinetics and pharmacodynamics of rilotumumab: a decade of experience in preclinical and clinical cancer research
Rilotumumab is a fully human monoclonal antibody against hepatocyte growth factor, the only known ligand of the MET receptor. Over the last decade, rilotumumab has been extensively tested in preclinical studies and in clinical studies in a variety of cancer types. In this review, we examine the phar...
Сохранить в:
| Опубликовано в: : | Br J Clin Pharmacol |
|---|---|
| Главные авторы: | , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
John Wiley & Sons, Ltd
2015
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4631169/ https://ncbi.nlm.nih.gov/pubmed/25912961 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.12663 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|